You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The development of drugs for treatment of sleeping sickness: a historical review
|
|---|---|
| Published in |
Parasites & Vectors, March 2010
|
| DOI | 10.1186/1756-3305-3-15 |
| Pubmed ID | |
| Authors |
Dietmar Steverding |
| Abstract |
Only four drugs are available for the chemotherapy of human African trypanosomiasis or sleeping sickness; Suramin, pentamidine, melarsoprol and eflornithine. The history of the development of these drugs is well known and documented. suramin, pentamidine and melarsoprol were developed in the first half of the last century by the then recently established methods of medicinal chemistry. Eflornithine, originally developed in the 1970s as an anti-cancer drug, became a treatment of sleeping sickness largely by accident. This review summarises the developmental processes which led to these chemotherapies from the discovery of the first bioactive lead compounds to the identification of the final drugs. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 1 | 17% |
| United Kingdom | 1 | 17% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Scientists | 2 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 324 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 1% |
| Chile | 1 | <1% |
| Germany | 1 | <1% |
| France | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 316 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 76 | 23% |
| Student > Bachelor | 43 | 13% |
| Student > Master | 33 | 10% |
| Researcher | 32 | 10% |
| Student > Doctoral Student | 13 | 4% |
| Other | 48 | 15% |
| Unknown | 79 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 77 | 24% |
| Chemistry | 52 | 16% |
| Biochemistry, Genetics and Molecular Biology | 45 | 14% |
| Medicine and Dentistry | 21 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 4% |
| Other | 32 | 10% |
| Unknown | 83 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2024.
All research outputs
#1,546,625
of 25,374,917 outputs
Outputs from Parasites & Vectors
#223
of 5,988 outputs
Outputs of similar age
#5,189
of 102,524 outputs
Outputs of similar age from Parasites & Vectors
#4
of 20 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,988 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 102,524 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.